Publications by authors named "Chaim Shustik"

Claim this Profile
O
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
Irit Avivi, David H Vesole, Julio Davila-Valls, Lidia Usnarska-Zubkiewicz, Magdalena Olszewska-Szopa, Chaim Shustik

Cancers (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Christian Buske, Alessandra Tedeschi, Judith Trotman, Ramón García-Sanz, David MacDonald, Chaim Shustik

Future Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
Robert Frank Cornell, Rachid Baz, Joshua R Richter, Adriana Rossi, Dan T Vogl, Chaim Shustik

Am J Hematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Christian Buske, Alessandra Tedeschi, Judith Trotman, Ramón García-Sanz, David MacDonald, Chaim Shustik

J Clin Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Andrew Belch, Nizar Bahlis, Darrell White, Matthew Cheung, Christine Chen, Chaim Shustik

Cancer Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Ajai Chari, Robert F Cornell, Cristina Gasparetto, Chatchada Karanes, Jeffrey V Matous, Chaim Shustik

Hematol Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous remission and clonal evolution in lenalidomide associated secondary AML.
Daniel D Waller, Yury Monczak, René P Michel, Chaim Shustik, Michael Sebag

Leuk Lymphoma· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García-Sanz, David Macdonald, Chaim Shustik

N Engl J Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Shaji Kumar, Philippe Moreau, Parameswaran Hari, Maria-Victoria Mateos, Heinz Ludwig, Chaim Shustik

Br J Haematol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Chaim Shustik

Lancet Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Cyrille Hulin, Andrew Belch, Chaim Shustik, Maria Teresa Petrucci, Ulrich Dührsen

J Clin Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.
Artur Jurczyszyn, Magdalena Olszewska-Szopa, Vania Hungria, Edvan Crusoe, Tomas Pika, Chaim Shustik

Leuk Lymphoma· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Artur Jurczyszyn, Norbert Grzasko, Alessandro Gozzetti, Jacek Czepiel, Alfonso Cerase, Chaim Shustik

Am J Hematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.
Francis Robert, William Roman, Alexandre Bramoullé, Christof Fellmann, Anne Roulston, Chaim Shustik

Proc Natl Acad Sci U S A· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Paul G Richardson, David S Siegel, Ravi Vij, Craig C Hofmeister, Rachid Baz, Chaim Shustik

Blood· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.
A Keith Stewart, Suzanne Trudel, Nizar J Bahlis, Darrell White, Waleed Sabry, Chaim Shustik

Blood· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
Ralph M Meyer, Mary K Gospodarowicz, Joseph M Connors, Robert G Pearcey, Woodrow A Wells, Chaim Shustik

N Engl J Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Donna E Reece, Dan Sullivan, Sagar Lonial, Ann F Mohrbacher, Gurkamal Chatta, Chaim Shustik

Cancer Chemother Pharmacol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Necrosis following skull base irradiation and stem cell transplant for multiple myeloma.
Sonia Skamene, Ronny L Rotondo, Chaim Shustik, David Roberge

Am J Hematol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate.
Hassan Huwait, Beatrice Wang, Chaim Shustik, René P Michel

Am J Dermatopathol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
Heinz Ludwig, Brian G M Durie, Vanessa Bolejack, Ingemar Turesson, Robert A Kyle, Chaim Shustik

Blood· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.
Chaim Shustik, Andrew Belch, Sue Robinson, Sheldon H Rubin, Sean P Dolan

Br J Haematol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Richard Van Der Jagt, K Sue Robinson, Andrew Belch, Elizabeth Yetisir, George Wells, Chaim Shustik

Leuk Lymphoma· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
William R Friedenberg, Montserrat Rue, Emily A Blood, William S Dalton, Chaim Shustik

Cancer· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Sarit Assouline, Marie-Pierre Sylvestre, Philippe Carriere, Chaim Shustik, Pierre Laneuville

Transfusion· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis